


PHARMACEUTICAL 2020

ADIAL PHARMACEUTICALS INC. Rank 173 of 358





PHARMACEUTICAL 2020

ADIAL PHARMACEUTICALS INC. Rank 173 of 358

The relative strengths and weaknesses of ADIAL PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ADIAL PHARMACEUTICALS INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 111% points. The greatest weakness of ADIAL PHARMACEUTICALS INC. is the variable Net Income, reducing the Economic Capital Ratio by 118% points.

The company's Economic Capital Ratio, given in the ranking table, is 90%, being 53% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	7,673
Cost of Goods Sold	0
Intangible Assets	6.2
Liabilities, Current	539
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-347
Other Revenues	0
Property and Equipment	0
Research and Development	3,966
Selling, General and Administrative Expense	4,279

Output Variable	Value in 1000 USD
Assets	7,680
Liabilities	539
Expenses	8,245
Revenues	0
Stockholders Equity	7,141
Net Income	-8,591
Comprehensive Net Income	-8,591
Economic Capital Ratio	90%

